Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | GPR3 | P46089 | 2/20 | 0.41 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.36 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2177659 | 0.80 | HTR2A (0.54) | HTR2ACA1CA2GPR3TDO2 | |
| SCHEMBL499696 | 0.78 | HTR2A (0.52) | HTR2ACA1CA2GPR3TDO2 | |
| SCHEMBL5353138 | 0.78 | HTR2A (0.64) | HTR2ACA1CA2GPR3TDO2 | |
| SCHEMBL7576966 | 0.78 | HTR2A (0.64) | HTR2ACA1CA2GPR3TDO2 | |
| SCHEMBL7574105 | 0.76 | HTR2A (0.61) | HTR2ACA1CA2GPR3TDO2 | |
| SCHEMBL17022715 | 0.76 | HTR2A (0.61) | HTR2ACA1CA2GPR3TDO2 | |
| SCHEMBL40598 | 0.75 | GPR3 (0.46) | HTR2AGPR3ACHECHRM2HTR1A | |
| SCHEMBL261028 | 0.74 | HTR2A (0.58) | HTR2ACA1CA2GPR3TDO2 | |
| SCHEMBL22664654 | 0.74 | HTR2A (0.58) | HTR2ACA1CA2GPR3TDO2 | |
| SCHEMBL633764 | 0.74 | HTR2A (0.58) | HTR2ACA1CA2GPR3TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 238 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110536895-A | SCN9A antisense analgesics | OLIPASS CORP | 2019-12-03 | — | — | CN | claimed |
| CN-110248956-A | HIF-1 α antisense oligonucleotides | 奥利通公司 | 2019-09-17 | — | — | CN | claimed |
| CN-110072879-A | Androgen receptor antisense oligonucleotides | 奥利通公司 | 2019-07-30 | — | — | CN | claimed |
| CN-109996807-A | SCN9A antisense oligonucleotides | 奥利通公司 | 2019-07-09 | — | — | CN | claimed |
| US-7989481-B2 | Indane derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-02 | — | — | US | claimed |
| EP-2319825-A1 | ENZYMATIC SYNTHESIS OF ENANTIOMERICALLY ENRICHED DERIVATIVES OF CIS- AND TRANS-CYCLOPENTANE-1,2-DIAMINES | EntreChem, S.L. (ES) | 2011-05-11 | — | — | EP | claimed |
| US-7605174-B2 | Indane derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-20 | — | — | US | claimed |
| EP-1888547-A1 | INDANE DERIVATIVES AS MODULATORS OF ION CHANNELS | Vertex Pharmaceuticals, Inc. (US) | 2008-02-20 | — | — | EP | claimed |
| US-7304086-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2007-12-04 | — | — | US | claimed |
| US-20070117801-A1 | Indane derivatives as modulator of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-05-24 | — | — | US | claimed |
| WO-2006133459-A1 | INDANE DERIVATIVES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-12-14 | — | — | WO | claimed |
| EP-0690856-A4 | — | UNIV NEW YORK (US) | 1996-02-07 | — | — | EP | claimed |
| EP-0690856-A1 | ANTI-TUMOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, METHODS FOR PREPARATION THEREOF AND FOR TREATMENT | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1996-01-10 | — | — | EP | claimed |
| US-5380835-A | Chemically phosphorylating the 5'-hydroxyl terminus of an oligonucleotide | ABBOTT LABORATORIES (US) | 1995-01-10 | — | — | US | claimed |
| WO-1994022856-A1 | ANTI-TUMOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, METHODS FOR PREPARATION THEREOF AND FOR TREATMENT | THE RESEARCH FOUNDATION OF THE STATE UNIVERSITY OF NEW YORK (US) | 1994-10-13 | — | — | WO | claimed |
| EP-0592534-A4 | SILYL PHOSPHORYLATING REAGENTS AND METHODS OF USING THEM | ABBOTT LAB (US) | 1994-07-06 | — | — | EP | claimed |
| EP-0592534-A1 | SILYL PHOSPHORYLATING REAGENTS AND METHODS OF USING THEM | ABBOTT LABORATORIES (US) | 1994-04-20 | — | — | EP | claimed |
| WO-1993012091-A1 | D- AND L-1,2,3,4-TETRAHYDRO-ISOQUINOLINE-1-CARBOXYLIC ACIDS AND THEIR DERIVATIVES CONTAINING URETHANE-TYPE N-PROTECTING GROUPS AS WELL AS A PROCESS FOR PREPARING THEM AND THE CORRESPONDING RACEMATES | Gyógyszerkutató Intézet Kft. (HU) | 1993-06-24 | — | — | WO | claimed |
| WO-1992021689-A1 | SILYL PHOSPHORYLATING REAGENTS AND METHODS OF USING THEM | ABBOTT LABORATORIES (US) | 1992-12-10 | — | — | WO | claimed |
| US-20240239745-A1 | METHOD FOR SYNTHESIZING BILIRUBIN | Bilix Co., Ltd. (KR) | 2024-07-18 | — | — | US | disclosed |
| EP-4375280-A1 | METHOD FOR SYNTHESIZING BILIRUBIN | Bilix Co., Ltd. (KR) | 2024-05-29 | — | — | EP | disclosed |
| EP-4371985-A1 | METHOD FOR SYNTHESIZING BILIRUBIN | Bilix Co., Ltd. (KR) | 2024-05-22 | — | — | EP | disclosed |
| EP-4371984-A1 | METHOD FOR SYNTHESIZING BILIRUBIN | Bilix Co., Ltd. (KR) | 2024-05-22 | — | — | EP | disclosed |
| CN-117881673-A | Synthesis method of bilirubin | 株式会社毕丽斯 | 2024-04-12 | — | — | CN | disclosed |
| CN-117836290-A | Synthesis method of bilirubin | 株式会社毕丽斯 | 2024-04-05 | — | — | CN | disclosed |
| CN-117813301-A | Synthesis method of bilirubin | 株式会社毕丽斯 | 2024-04-02 | — | — | CN | disclosed |
| CN-117716054-A | Heat treatment oil composition | 出光兴产株式会社 | 2024-03-15 | — | — | CN | disclosed |
| CN-117480235-A | Heat treatment oil composition | 出光兴产株式会社 | 2024-01-30 | — | — | CN | disclosed |
| US-11860540-B2 | Positive resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2024-01-02 | — | — | US | disclosed |
| US-11846884-B2 | Chemically amplified resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-12-19 | — | — | US | disclosed |
| US-11835859-B2 | Resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-12-05 | — | — | US | disclosed |
| US-11733608-B2 | Resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-08-22 | — | — | US | disclosed |
| WO-2023101004-A1 | OLEFIN RESIN, METHOD FOR MANUFACTURING SAME, AND APPLICATION FOR SAME | 三井化学株式会社 | 2023-06-08 | — | — | WO | disclosed |
| CN-116165846-A | Positive resist material and pattern forming method | 信越化学工业株式会社 | 2023-05-26 | — | — | CN | disclosed |
| US-20230161252-A1 | POSITIVE RESIST COMPOSITION AND PATTERN FORMING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-05-25 | — | — | US | disclosed |
| US-20230152692-A1 | CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-05-18 | — | — | US | disclosed |
| US-11644753-B2 | Resist composition and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-05-09 | — | — | US | disclosed |
| US-20230131303-A1 | RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-04-27 | — | — | US | disclosed |
| US-20230129578-A1 | RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-04-27 | — | — | US | disclosed |
| US-20230120132-A1 | RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-04-20 | — | — | US | disclosed |
| CN-115710274-A | IRAK4 degradation agent, preparation method and application thereof | 上海领泰生物医药科技有限公司 | 2023-02-24 | — | — | CN | disclosed |
| WO-2023018215-A1 | METHOD FOR SYNTHESIZING BILIRUBIN | 주식회사 빌릭스 | 2023-02-16 | — | — | WO | disclosed |
| WO-2023018214-A1 | METHOD FOR SYNTHESIZING BILIRUBIN | 주식회사 빌릭스 | 2023-02-16 | — | — | WO | disclosed |
| WO-2023018217-A1 | METHOD FOR SYNTHESIZING BILIRUBIN | 주식회사 빌릭스 | 2023-02-16 | — | — | WO | disclosed |
| WO-2023008545-A1 | HEAT-TREATMENT OIL COMPOSITION | 出光興産株式会社 | 2023-02-02 | — | — | WO | disclosed |
| US-20230021453-A1 | RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2023-01-26 | — | — | US | disclosed |
| WO-2022264951-A1 | HEAT-TREATMENT OIL COMPOSITION | 出光興産株式会社 | 2022-12-22 | — | — | WO | disclosed |
| US-20220393237-A1 | POLYMER, ADDITIVE FOR NONAQUEOUS ELECTROLYTE SOLUTIONS, NONAQUEOUS ELECTROLYTE SOLUTION, AND LITHIUM ION SECONDARY BATTERY | NISSAN CHEMICAL CORPORATION (JP) | 2022-12-08 | — | — | US | disclosed |
| US-20220026803-A1 | RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2022-01-27 | — | — | US | disclosed |
| US-20220004100-A1 | RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2022-01-06 | — | — | US | disclosed |
| US-20220004101-A1 | CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2022-01-06 | — | — | US | disclosed |
| US-20210405528-A1 | RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2021-12-30 | — | — | US | disclosed |
| EP-3929228-A1 | BATTERY MATERIAL AND ELECTRODE MATERIAL | Nissan Chemical Corporation (JP) | 2021-12-29 | — | — | EP | disclosed |
| US-20210364921-A1 | POSITIVE RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2021-11-25 | — | — | US | disclosed |
| US-20210294211-A1 | RESIST COMPOSITION AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2021-09-23 | — | — | US | disclosed |
| US-20210151797-A1 | ADDITIVE FOR NONAQUEOUS ELECTROLYTE SOLUTIONS, NONAQUEOUS ELECTROLYTE SOLUTION, AND LITHIUM ION SECONDARY BATTERY | NISSAN CHEMICAL CORPORATION (JP) | 2021-05-20 | — | — | US | disclosed |
| WO-2021065844-A1 | POLYMER, ADDITIVE FOR NONAQUEOUS ELECTROLYTE SOLUTIONS, NONAQUEOUS ELECTROLYTE SOLUTION, AND LITHIUM ION SECONDARY BATTERY | 日産化学株式会社 | 2021-04-08 | — | — | WO | disclosed |
| CN-110551098-B | Oxime ester photoinitiator containing five-membered aromatic heterocyclic structure and preparation and application thereof | 湖北固润科技股份有限公司 | 2021-03-12 | — | — | CN | disclosed |
| US-20210060168-A1 | ASIALOGLYCOPROTEIN RECEPTOR MEDIATED DELIVERY OF THERAPEUTICALLY ACTIVE CONJUGATES | ARCTURUS THERAPEUTICS, INC. | 2021-03-04 | — | — | US | disclosed |
| EP-3780229-A1 | ADDITIVE FOR NONAQUEOUS ELECTROLYTE SOLUTIONS, NONAQUEOUS ELECTROLYTE SOLUTION, AND LITHIUM ION SECONDARY BATTERY | Nissan Chemical Corporation (JP) | 2021-02-17 | — | — | EP | disclosed |
| EP-3768256-A1 | PAN-TROPIC ENTRY INHIBITORS | Emory University (US) | 2021-01-27 | — | — | EP | disclosed |
| WO-2020252628-A1 | OXIME ESTER PHOTOINITIATORS CONTAINING FIVE-MEMBERED HETEROAROMATIC RING STRUCTURE, AND PREPARATION AND USE THEREOF | 湖北固润科技股份有限公司 | 2020-12-24 | — | — | WO | disclosed |
| US-20200384111-A1 | MODIFIED CARBON NANOMATERIAL, NANOCLUSTER, SUBSTANCE DELIVERY CARRIER, AND PHARMACEUTICAL COMPOSITION | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2020-12-10 | — | — | US | disclosed |
| CN-111971843-A | Additive for nonaqueous electrolyte solution, and lithium ion secondary battery | 日产化学株式会社 | 2020-11-20 | — | — | CN | disclosed |
| EP-3725331-A1 | MODIFIED CARBON NANOMATERIAL, NANOCLUSTER, SUBSTANCE DELIVERY CARRIER, AND PHARMACEUTICAL COMPOSITION | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2020-10-21 | — | — | EP | disclosed |
| CN-111727061-A | Modified carbon nanomaterial, nanocluster, substance delivery carrier and pharmaceutical composition | 国立研究开发法人产业技术总合研究所 | 2020-09-29 | — | — | CN | disclosed |
| EP-3601283-A1 | FUSED IMIDAZO-PIPERIDINE JAK INHIBITOR COMPOUND | Theravance Biopharma R&D IP, LLC (US) | 2020-02-05 | — | — | EP | disclosed |
| CN-110551098-A | oxime ester photoinitiator containing five-membered aromatic heterocyclic structure and preparation and application thereof | HUBEI GURUN TECH CO LTD | 2019-12-10 | — | — | CN | disclosed |
| CN-110536895-A | SCN9A antisense analgesics | OLIPASS CORP | 2019-12-03 | — | — | CN | disclosed |
| CN-110506051-A | Exon skipping by peptide nucleic acid derivatives | OLIPASS CORP | 2019-11-26 | — | — | CN | disclosed |
| WO-2019183133-A1 | Pan-Tropic Entry Inhibitors | EMORY UNIVERSITY (US) | 2019-09-26 | — | — | WO | disclosed |
| CN-110248956-A | HIF-1 α antisense oligonucleotides | 奥利通公司 | 2019-09-17 | — | — | CN | disclosed |
| CN-110072879-A | Androgen receptor antisense oligonucleotides | 奥利通公司 | 2019-07-30 | — | — | CN | disclosed |
| CN-109996807-A | SCN9A antisense oligonucleotides | 奥利通公司 | 2019-07-09 | — | — | CN | disclosed |
| CN-109514776-A | Make the method and device thereof that molding is demoulded from mold | SKC株式会社 | 2019-03-26 | — | — | CN | disclosed |
| WO-2018204238-A1 | FUSED IMIDAZO-PIPERIDINE JAK INHIBITOR COMPOUND | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-11-08 | — | — | WO | disclosed |
| US-9151888-B2 | Optical waveguide and electronic device | SUMITOMO BAKELITE CO., LTD. (JP) | 2015-10-06 | — | — | US | disclosed |
| US-20150272947-A1 | INHIBITORS OF PROTEIN KINASES | ASTRAZENECA AB (SE) | 2015-10-01 | — | — | US | disclosed |
| EP-2089383-B1 | 3-HYDR0XY-1,5-DIHYDR0-PYRR0L-2-ONE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE FOR THE TREATMENT OF ULCER, CANCER AND OTHER DISEASES | PROBIODRUG AG (DE) | 2015-09-16 | — | — | EP | disclosed |
| US-9126987-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2015-09-08 | — | — | US | disclosed |
| US-9067888-B2 | Inhibitors of protein kinases | ASTRAZENECA AB (SE) | 2015-06-30 | — | — | US | disclosed |
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| CN-102834380-B | Inhibitors of protein kinases | ASTRAZENECA | 2015-04-01 | — | — | CN | disclosed |
| WO-2014108526-A1 | SYNTHETIC PROCESS FOR THE MANUFACTURE OF PIPECOLIDEPSIN COMPOUNDS | PHARMA MAR, S.A. (ES) | 2014-07-17 | — | — | WO | disclosed |
| EP-2086960-B1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2014-03-05 | — | — | EP | disclosed |
| EP-2091945-B1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2014-01-15 | — | — | EP | disclosed |
| US-20130345233-A1 | INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-12-26 | — | — | US | disclosed |
| US-8518948-B2 | Inhibitors of protein kinases | INGENIUM PHARMACEUTICALS GMBH (DE) | 2013-08-27 | — | — | US | disclosed |
| US-20130170803-A1 | OPTICAL WAVEGUIDE AND ELECTRONIC DEVICE | SUMITOMO BAKELITE CO., LTD. (JP) | 2013-07-04 | — | — | US | disclosed |
| US-20130158071-A1 | PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-20 | — | — | US | disclosed |
| US-8420684-B2 | imidazole derivatives; Alzheimer's Disease, Down syndrome, Huntington's Disease; hypotensive agents; sleeping/eating disorders, anxiolytic agents, antidepressants, antiepileptic agents; drug abuse/withdrawl; 4-Cyclopropylimino-5-(3,4-dihydro-2H-pyran-2-yl)-1-(3-imidazol-1-yl-propyl)-imidazolidin-2-one | PROBIODRUG AG (DE) | 2013-04-16 | — | — | US | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-2373661-B1 | NEW STEREOSPECIFIC METHOD FOR THE PREPARATION OF DIOXA-BICYCLOOCTANE NITRATE COMPOUNDS | LACER SA (ES) | 2013-03-20 | — | — | EP | disclosed |
| EP-2545037-A1 | INHIBITORS OF PROTEIN KINASES | Ingenium Pharmaceuticals GmbH (DE) | 2013-01-16 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| CN-102834380-A | Inhibitors of protein kinases | INGENIUM PHARMACEUTICALS GMBH | 2012-12-19 | — | — | CN | disclosed |
| CN-102822169-A | Substituted naphthyl-pyrimidine compounds | ARQULE INC | 2012-12-12 | — | — | CN | disclosed |
| EP-2519519-A2 | SUBSTITUTED NAPHTHALENYL-PYRIMIDINE COMPOUNDS | ArQule, Inc. (US) | 2012-11-07 | — | — | EP | disclosed |
| US-8278345-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2012-10-02 | — | — | US | disclosed |
| US-8273766-B2 | Tetrahydroisoquinoline compound | KOWA COMPANY, LTD. (JP) | 2012-09-25 | — | — | US | disclosed |
| CN-102532162-A | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2012-07-04 | — | — | CN | disclosed |
| US-8173808-B2 | Substituted naphthalenyl-pyrimidine compounds | ARQULE, INC. (US) | 2012-05-08 | — | — | US | disclosed |
| EP-2091948-B1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2012-04-18 | — | — | EP | disclosed |
| US-8106224-B2 | Stereospecific method for the preparation of dioxa-bicyclooctane nitrate compounds | LACER, S.A. (ES) | 2012-01-31 | — | — | US | disclosed |
| EP-1713780-B1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2012-01-18 | — | — | EP | disclosed |
| US-20110251409-A1 | STEREOSPECIFIC METHOD FOR THE PREPARATION OF DIOXA-BICYCLOOCTANE NITRATE COMPOUNDS | LACER, S.A. (ES) | 2011-10-13 | — | — | US | disclosed |
| US-20110224225-A1 | Inhibitors of protein kinases | ASTRAZENECA AB (SE) | 2011-09-15 | — | — | US | disclosed |
| WO-2011110612-A1 | INHIBITORS OF PROTEIN KINASES | INGENIUM PHARMACEUTICALS GMBH (DE) | 2011-09-15 | — | — | WO | disclosed |
| US-7989481-B2 | Indane derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-08-02 | — | — | US | disclosed |
| CN-102137868-A | Prophylactic or therapeutic agent for influenza virus infection | UNIV KEIO | 2011-07-27 | — | — | CN | disclosed |
| CN-102132180-A | Film for optical waveguide, film for laminated optical waveguide, optical waveguide assembly, optical wiring, opto-electric hybrid substrate, and electronic device | SUMITOMO BAKELITE CO | 2011-07-20 | — | — | CN | disclosed |
| WO-2011082268-A2 | SUBSTITUTED NAPHTHALENYL-PYRIMIDINE COMPOUNDS | ARQULE INC. (US) | 2011-07-07 | — | — | WO | disclosed |
| US-20110166137-A1 | Substituted Naphthalenyl-Pyrimidine Compounds | ARQULE, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110152178-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR INFLUENZA VIRUS INFECTION | KEIO UNIVERSITY (JP) | 2011-06-23 | — | — | US | disclosed |
| EP-2327714-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR INFLUENZA VIRUS INFECTION | Keio University (JP) | 2011-06-01 | — | — | EP | disclosed |
| US-20110117651-A1 | CELL ADHESION PROMOTING AGENT AND METHOD OF PROMOTING CELL ADHESION | KYOTO UNIVERSITY (JP) | 2011-05-19 | — | — | US | disclosed |
| EP-2149577-B1 | New stereospecific method for the preparation of dioxa-bicyclooctane compounds | LACER SA (ES) | 2011-04-27 | — | — | EP | disclosed |
| EP-2308960-A1 | CELL ADHESION PROMOTING AGENT AND METHOD OF PROMOTING CELL ADHESION | Kyoto University (JP) | 2011-04-13 | — | — | EP | disclosed |
| US-7897633-B2 | Neuronal disorders such as Alzheimer's disease, Down Syndrome, Parkinson disease, Chorea Huntington, pathogenic psychotic conditions, schizophrenia, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function; alcoholism | PROBIODRUG AG (DE) | 2011-03-01 | — | — | US | disclosed |
| US-20100234397-A1 | ENZYME INHIBITORS | PROBIODRUG AG (DE) | 2010-09-16 | — | — | US | disclosed |
| US-20100160652-A1 | STEREOSPECIFIC METHOD FOR THE PREPARATION OF DIOXA-BICYCLOOCTANE NITRATE COMPOUNDS | LACER, S.A. (ES) | 2010-06-24 | — | — | US | disclosed |
| EP-2199294-A1 | New stereospecific method for the preparation of dioxa bicyclooctane nitrate compounds | LACER, S.A. (ES) | 2010-06-23 | — | — | EP | disclosed |
| US-7741354-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2010-06-22 | — | — | US | disclosed |
| US-7728146-B2 | Enzyme inhibitors | PROBIODRUG AG (DE) | 2010-06-01 | — | — | US | disclosed |
| WO-2010055138-A1 | NEW STEREOSPECIFIC METHOD FOR THE PREPARATION OF DIOXA-BICYCLOOCTANE COMPOUNDS | LACER, S.A. (ES) | 2010-05-20 | — | — | WO | disclosed |
| US-20100099721-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PROBIODRUG AG (DE) | 2010-04-22 | — | — | US | disclosed |
| US-7667044-B2 | treating nervous system diorders such as Alzheimer's disease, Down Syndrome, Parkinson disease and Huntington chorea by administering inhibitors of prolyl endopeptidases | PROBIODRUG AG (DE) | 2010-02-23 | — | — | US | disclosed |
| EP-2149577-A1 | New stereospecific method for the preparation of dioxa-bicyclooctane compounds | LACER, S.A. (ES) | 2010-02-03 | — | — | EP | disclosed |
| US-20090326023-A1 | Indane Derivatives as Modulators of ION Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-12-31 | — | — | US | disclosed |
| US-7635782-B1 | Stereospecific method for the preparation of dioxa-bicyclooctane compounds | LACER, S.A. (ES) | 2009-12-22 | — | — | US | disclosed |
| US-7625939-B2 | Cyclopropyl-fused pyrrolidine derivatives as dipeptidyl peptidase IV inhibitors | PROBIODRUG AG (DE) | 2009-12-01 | — | — | US | disclosed |
| US-20090269301-A1 | Novel Inhibitors of Glutaminyl Cyclase | PROBIODRUG AG (DE) | 2009-10-29 | — | — | US | disclosed |
| US-7605174-B2 | Indane derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-20 | — | — | US | disclosed |
| EP-2091948-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | Probiodrug AG (DE) | 2009-08-26 | — | — | EP | disclosed |
| EP-2091945-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | Probiodrug AG (DE) | 2009-08-26 | — | — | EP | disclosed |
| EP-2089383-A1 | 3-HYDR0XY-1,5-DIHYDR0-PYRR0L-2-ONE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE FOR THE TREATMENT OF ULCER, CANCER AND OTHER DISEASES | Probiodrug AG (DE) | 2009-08-19 | — | — | EP | disclosed |
| EP-2086960-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | Probiodrug AG (DE) | 2009-08-12 | — | — | EP | disclosed |
| CN-101466685-A | Enzyme inhibitors | PROBIODRUG AG (DE) | 2009-06-24 | — | — | CN | disclosed |
| WO-2009063235-A1 | DERIVATIVES OF 1,9-DIHYDRO-6H-PURIN-6-ONE AND USES THEREOF-018 | ASTRAZENECA AB (SE) | 2009-05-22 | — | — | WO | disclosed |
| US-7514452-B2 | 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same | DAINIPPON PHARMACEUTICAL CO., LTD (JP) | 2009-04-07 | — | — | US | disclosed |
| WO-2009034386-A1 | DERIVATIVES OF ADENINE AND 8-AZA-ADENINE AND USES THEREOF-796 | ASTRAZENECA AB (SE) | 2009-03-19 | — | — | WO | disclosed |
| US-20090018087-A1 | Novel Inhibitors of Glutaminyl Cyclase | PROBIODRUG AG (DE) | 2009-01-15 | — | — | US | disclosed |
| EP-2010475-A2 | HETEROFUNCTIONAL POLY(ETHYLENE GLYCOL) CONTAINING ACID-LABILE AMINO PROTECTING GROUPS AND USES THEREOF | Intezyne Technologies Incorporated (US) | 2009-01-07 | — | — | EP | disclosed |
| EP-2007734-A1 | ENZYME INHIBITORS | Probiodrug AG (DE) | 2008-12-31 | — | — | EP | disclosed |
| US-20080293618-A1 | CYCLOPROPYL-FUSED PYRROLIDINE DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | PROBIODRUG AG (DE) | 2008-11-27 | — | — | US | disclosed |
| EP-1971614-A1 | CYCLOPROPYL-FUSED PYRROLIDINE DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | Probiodrug AG (DE) | 2008-09-24 | — | — | EP | disclosed |
| US-20080221086-A1 | Novel Inhibitors of Glutaminyl Cyclase | PROBIODRUG AG (DE) | 2008-09-11 | — | — | US | disclosed |
| US-20080214620-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-09-04 | — | — | US | disclosed |
| CN-101255170-A | 2,3-dihydroimidazo[2,1-b]oxazole compound | OTSUKA PHARMA CO LTD (JP) | 2008-09-03 | — | — | CN | disclosed |
| US-20080207715-A1 | Novel Inhibitors of Glutaminyl Cyclase | PROBIODRUG AG (DE) | 2008-08-28 | — | — | US | disclosed |
| US-20080200475-A1 | 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors | PFIZER INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080194590-A1 | 4-Piperazinylthieno [2,3-D] Pyrimidine Compounds as Platelet Aggregation Inhibitors | PFIZER INC | 2008-08-14 | — | — | US | disclosed |
| US-20080176857-A1 | 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors | PFIZER INC. | 2008-07-24 | — | — | US | disclosed |
| WO-2008065141-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008055945-A1 | 3-HYDR0XY-1,5-DIHYDR0-PYRR0L-2-ONE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE FOR THE TREATMENT OF ULCER, CANCER AND OTHER DISEASES | PROBIODRUG AG (DE) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008055947-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008055950-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2008-05-15 | — | — | WO | disclosed |
| CN-101172981-A | 2,3-dihydroimidazo[2,1-b]oxazole compound | OTSUKA PHARMA CO LTD (JP) | 2008-05-07 | — | — | CN | disclosed |
| EP-1900726-A1 | Heterocyclic thioesters | MGI GP, Inc. (US) | 2008-03-19 | — | — | EP | disclosed |
| EP-1896483-A2 | 4-PIPERAZINYLTHIENO [2, 3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | Pharmacia & Upjohn Company LLC (US) | 2008-03-12 | — | — | EP | disclosed |
| EP-1888547-A1 | INDANE DERIVATIVES AS MODULATORS OF ION CHANNELS | Vertex Pharmaceuticals, Inc. (US) | 2008-02-20 | — | — | EP | disclosed |
| CN-100366624-C | 2, 3-dihydro-6-nitroimidazo [2,1-b ] * azole compounds | OTSUKA PHARMA CO LTD (JP) | 2008-02-06 | — | — | CN | disclosed |
| EP-1874780-A1 | 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | Pharmacia & Upjohn Company LLC (US) | 2008-01-09 | — | — | EP | disclosed |
| EP-1869051-A1 | 4-PIPERAZINYLTHIENO Ý2,3-D¨PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | Pharmacia & Upjohn Company LLC (US) | 2007-12-26 | — | — | EP | disclosed |
| EP-1866317-A1 | 4-PIPERAZINOTHIENO [2, 3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | Pharmacia & Upjohn Company LLC (US) | 2007-12-19 | — | — | EP | disclosed |
| US-7304086-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2007-12-04 | — | — | US | disclosed |
| WO-2007127440-A2 | HETEROFUNCTIONAL POLY(ETHYLENE GLYCOL) CONTAINING ACID-LABILE AMINO PROTECTING GROUPS AND USES THEREOF | INTEZYNE TECHNOLOGIES, INC. (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20070244177-A1 | ENZYME INHIBITORS | PROBIODRUG AG (DE) | 2007-10-18 | — | — | US | disclosed |
| WO-2007116092-A1 | ENZYME INHIBITORS | PROBIODRUG AG (DE) | 2007-10-18 | — | — | WO | disclosed |
| EP-1844052-A1 | THIENO[2,3-D]PYRIMIDINE COMPOUNDS AS INHIBITORS OF ADP-MEDIATED PLATELETS AGGREGATION | Pharmacia & Upjohn Company LLC (US) | 2007-10-17 | — | — | EP | disclosed |
| EP-1824846-A2 | NOVEL COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Probiodrug AG (DE) | 2007-08-29 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| EP-1809299-A2 | PHOSPHONATE SUBSTITUTED KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2007-07-25 | — | — | EP | disclosed |
| US-20070117801-A1 | Indane derivatives as modulator of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-05-24 | — | — | US | disclosed |
| WO-2007054577-A1 | CYCLOPROPYL-FUSED PYRROLIDINE DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | PROBIODRUG AG (DE) | 2007-05-18 | — | — | WO | disclosed |
| WO-2006133459-A1 | INDANE DERIVATIVES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-12-14 | — | — | WO | disclosed |
| EP-1713780-A2 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | Probiodrug AG (DE) | 2006-10-25 | — | — | EP | disclosed |
| WO-2006103544-A2 | 4-PIPERAZINYLTHIENO [2, 3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006103545-A1 | 4-PIPERAZINYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006103555-A1 | 4-PIPERAZINOTHIENO [2, 3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-10-05 | — | — | WO | disclosed |
| WO-2006100591-A1 | 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-09-28 | — | — | WO | disclosed |
| US-7094516-B2 | Benzobisazole compound and optical recording medium containing the compound | MITSUI CHEMICALS, INC. (JP) | 2006-08-22 | — | — | US | disclosed |
| EP-1083873-B1 | HETEROCYCLIC THIOESTER AND KETONE HAIR GROWTH COMPOSITIONS AND USES | MGI GP INC (US) | 2006-08-09 | — | — | EP | disclosed |
| WO-2006079916-A1 | THIENO [2,3-D] PYRIMIDINE COMPOUNDS AS INHIBITORS OF ADP-MEDIATED PLATELETS AGGREGATION | PHARMACIA & UPJOHN COMPANY LLC (US) | 2006-08-03 | — | — | WO | disclosed |
| WO-2006058720-A2 | NOVEL COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PROBIODRUG AG (DE) | 2006-06-08 | — | — | WO | disclosed |
| US-20060100253-A1 | Novel compounds for the treatment of neurological disorders | PROBIODRUG AG | 2006-05-11 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| WO-2006047507-A2 | PHOSPHONATE SUBSTITUTED KINASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2006-05-04 | — | — | WO | disclosed |
| US-20060088786-A1 | Rewritable optical information recording medium, recording and reproducing methods, as well as recording and reproducing apparatus | MITSUI CHEMICALS, INC. (JP) | 2006-04-27 | — | — | US | disclosed |
| EP-1626043-A1 | Heterocyclic thioesters | MGI GP, Inc. (US) | 2006-02-15 | — | — | EP | disclosed |
| US-6984639-B2 | Heterocyclic ketone and thioester compounds and uses | GPI NIL HOLDINGS, INC. (US) | 2006-01-10 | — | — | US | disclosed |
| CN-1705670-A | 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds | OTSUKA PHARMA CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| EP-0934263-B1 | NON-IMMUNOSUPPRESSANT FKBP ROTAMASE INHIBITORS | GUILFORD PHARM INC (US) | 2005-11-23 | — | — | EP | disclosed |
| US-20050215573-A1 | Novel inhibitors of glutaminyl cyclase | PROBIODRUG AG | 2005-09-29 | — | — | US | disclosed |
| WO-2005075436-A2 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2005-08-18 | — | — | WO | disclosed |
| US-20050171196-A1 | 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-20050148637-A1 | Heterocyclic ketone and thioester compounds and uses | GPI NIL HOLDINGS, INC. | 2005-07-07 | — | — | US | disclosed |
| EP-1180765-B1 | Optical recording medium and porphycene compound | MITSUI CHEMICALS INC (JP) | 2005-04-06 | — | — | EP | disclosed |
| US-20050059693-A1 | Heterocyclic thioester and ketone hair growth compositions and uses | GPI NIL HOLDINGS, INC. | 2005-03-17 | — | — | US | disclosed |
| EP-1489077-A1 | 2-FURANCARBOXYLIC ACID HYDRAZIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2004-12-22 | — | — | EP | disclosed |
| EP-1484191-A1 | REWRITABLE OPTICAL INFORMATION RECORDING MEDIUM AND RECORDING/REPRODUCING METHOD, RECORDING/REPRODUCING DEVICE | Sony Corporation (JP) | 2004-12-08 | — | — | EP | disclosed |
| EP-1479373-A1 | Hair growth compositions and uses | GPI NIL Holdings, Inc. (US) | 2004-11-24 | — | — | EP | disclosed |
| US-20040209860-A1 | compounds having a (biphenyl-2-yl)oxycarbonylamino- or (biphenyl-2-yl)aminocarbonylamino-substituted (2-7C)azacycloalkyl or (5-10C)azabicycloalkyl group; and a 2-(4-hydroxyphenyl)-2-hydroxyethylamino group; treating asthma or chronic obstructive pulmonary disease; providing bronchodilation | THERAVANCE RESPIRATORY COMPANY, LLC | 2004-10-21 | — | — | US | disclosed |
| EP-0983054-B1 | HAIR GROWTH COMPOSITIONS AND USES | GUILFORD PHARM INC (US) | 2004-09-15 | — | — | EP | disclosed |
| US-6627288-B1 | Optical recording medium and porphycene compound | MITSUI CHEMICALS, INC. (JP) | 2003-09-30 | — | — | US | disclosed |
| US-20030091931-A1 | Benzbisazole compound and optical recording medium containing the compound | MITSUI CHEMICALS, INC. (JP) | 2003-05-15 | — | — | US | disclosed |
| EP-1245571-A1 | BENZBISAZOLE COMPOUND AND OPTICAL RECORDING MEDIUM CONTAINING THE COMPOUND | Mitsui Chemicals, Inc. (JP) | 2002-10-02 | — | — | EP | disclosed |
| EP-1233945-A1 | HETEROCYCLIC KETONE AND THIOESTER COMPOUNDS AND USES | GPI NIL Holdings, Inc. (US) | 2002-08-28 | — | — | EP | disclosed |
| US-6417209-B2 | NON-IMMUNOSUPPRESSIVE, PIPERIDINO OR PYRROLIDINO AMIDE DERIVATIVE HAS AN AFFINITY FOR AN FKBP-TYPE IMMUNOPHILIN, USEFUL FOR TREATING ALZHEIMER'S DISEASE, HUNTINGTON'S DISEASE, PARKINSON'S DISEASE, AMYOTROPHIC LATERAL SCLEROSIS | GPI NIL HOLDINGS, INC. | 2002-07-09 | — | — | US | disclosed |
| US-6384056-B1 | COGNITION ACTIVATORS AND NERVE AND VISION DISORDERS | GPI NIL HOLDINGS, INC. | 2002-05-07 | — | — | US | disclosed |
| EP-1180765-A1 | Optical recording medium and porphycene compound | Mitsui Chemicals, Inc. (JP) | 2002-02-20 | — | — | EP | disclosed |
| EP-1127049-A1 | BRIDGED HETEROCYCLIC DERIVATIVES | GPI NIL Holdings, Inc. (US) | 2001-08-29 | — | — | EP | disclosed |
| US-6274602-B1 | ADMINISTERING COMPOSTITIONS SUCH AS 3,3-DIMETHYL-1-((2S)-2-(5-(3-PYRIDYL) PENTANOYL)-1-PYRROLIDINE)-1, 2-PENTANEDIONE TO TREAT ALOPECIA OR PROMOTING HAIR GROWTH IN ANIMALS | GPI NIL HOLDINGS, INC. | 2001-08-14 | — | — | US | disclosed |
| WO-2001038304-A1 | HETEROCYCLIC KETONE AND THIOESTER COMPOUNDS AND USES | GPI NIL HOLDINGS, INC. (US) | 2001-05-31 | — | — | WO | disclosed |
| US-6218424-B1 | FOR EFFECTING NEURONAL ACTIVITIES IN ANIMALS, INCLUDING TREATING NEUROLOGICAL DISORDERS | GPI NIL HOLDINGS, INC. | 2001-04-17 | — | — | US | disclosed |
| EP-1083873-A1 | HETEROCYCLIC THIOESTER AND KETONE HAIR GROWTH COMPOSITIONS AND USES | GPI NIL Holdings, Inc. (US) | 2001-03-21 | — | — | EP | disclosed |
| EP-1011650-A1 | METHOD FOR PREVENTING AND TREATING HEARING LOSS USING SENSORINEUROTROPHIC COMPOUNDS | Amgen Inc., (US) | 2000-06-28 | — | — | EP | disclosed |
| WO-2000016603-A2 | BRIDGED HETEROCYCLIC DERIVATIVES | GPI NIL HOLDINGS, INC. (US) | 2000-03-30 | — | — | WO | disclosed |
| EP-0983054-A1 | HAIR GROWTH COMPOSITIONS AND USES | GPI NIL Holdings, Inc. (US) | 2000-03-08 | — | — | EP | disclosed |
| WO-1999062488-A1 | HETEROCYCLIC THIOESTER AND KETONE HAIR GROWTH COMPOSITIONS AND USES | GPI NIL HOLDINGS, INC. (US) | 1999-12-09 | — | — | WO | disclosed |
| WO-1999014998-A2 | METHOD FOR PREVENTING AND TREATING HEARING LOSS USING SENSORINEUROTROPHIC COMPOUNDS | AMGEN INC. (US) | 1999-04-01 | — | — | WO | disclosed |
| WO-1998055090-A1 | HAIR GROWTH COMPOSITIONS AND USES | GUILFORD PHARMACEUTICALS INC. (US) | 1998-12-10 | — | — | WO | disclosed |
| US-5472973-A | Non-steroidal antiinflammatory agents | SCIOS NOVA INC. (US) | 1995-12-05 | — | — | US | disclosed |
| WO-1995026976-A1 | CYCLOPROPYL BASED O- AND N- AND S-PROTECTING GROUPS | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1995-10-12 | — | — | WO | disclosed |
| US-5380835-A | Chemically phosphorylating the 5'-hydroxyl terminus of an oligonucleotide | ABBOTT LABORATORIES (US) | 1995-01-10 | — | — | US | disclosed |
| EP-0591344-A4 | — | — | 1994-08-03 | — | — | EP | disclosed |
| EP-0591302-A4 | — | — | 1994-08-03 | — | — | EP | disclosed |
| EP-0592534-A4 | SILYL PHOSPHORYLATING REAGENTS AND METHODS OF USING THEM | ABBOTT LAB (US) | 1994-07-06 | — | — | EP | disclosed |
| EP-0592534-A1 | SILYL PHOSPHORYLATING REAGENTS AND METHODS OF USING THEM | ABBOTT LABORATORIES (US) | 1994-04-20 | — | — | EP | disclosed |
| EP-0591344-A1 | A PROCESS FOR SYNTHESIS OF SILYL ALCOHOLS | ABBOTT LABORATORIES (US) | 1994-04-13 | — | — | EP | disclosed |
| EP-0591302-A1 | SUBSTITUTED SILYL ALCOHOLS | ABBOTT LABORATORIES (US) | 1994-04-13 | — | — | EP | disclosed |
| WO-1993011764-A1 | FLUORENYL DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | SCIOS NOVA INC. (US) | 1993-06-24 | — | — | WO | disclosed |
| WO-1992022557-A1 | SUBSTITUTED SILYL ALCOHOLS | ABBOTT LABORATORIES (US) | 1992-12-23 | — | — | WO | disclosed |
| WO-1992022561-A1 | A PROCESS FOR SYNTHESIS OF SILYL ALCOHOLS | ABBOTT LABORATORIES (US) | 1992-12-23 | — | — | WO | disclosed |
| WO-1992021689-A1 | SILYL PHOSPHORYLATING REAGENTS AND METHODS OF USING THEM | ABBOTT LABORATORIES (US) | 1992-12-10 | — | — | WO | disclosed |
| US-5159095-A | Reagant for phosphorylating oligonucleotides | ABBOTT LABORATORIES (US) | 1992-10-27 | — | — | US | disclosed |
| US-5113005-A | Hydrosilation | ABBOTT LABORATORIES (US) | 1992-05-12 | — | — | US | disclosed |
| US-5113005-A | Hydrosilation | ABBOTT LABORATORIES (US) | 1992-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (38 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251409-A1 | STEREOSPECIFIC METHOD FOR THE PREPARATION OF DIOXA-BICYCLOOCTANE NITRATE COMPOUNDS | TST, NOS3, NOS1 | HTR2A 2647/4885CA1 132/4885CA2 55/4885 |
| US-20210294211-A1 | RESIST COMPOSITION AND PATTERNING PROCESS | HNRNPU, INSR, BICRA | HTR2A 3914/4885CA1 3056/4885CA2 2081/4885 |
| US-20130345233-A1 | INHIBITORS OF PROTEIN KINASES | CDK1, CDK2, CDK3 | HTR2A 3083/4885CA1 4127/4885CA2 3147/4885 |
| US-20090326023-A1 | Indane Derivatives as Modulators of ION Channels | KCNJ2, TRPV1, KCNJ1 | HTR2A 413/4885CA1 1089/4885CA2 178/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | HTR2A 4120/4885CA1 3493/4885CA2 1853/4885 |
| US-20100099721-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PREP, BACE1, BCHE | HTR2A 1419/4885CA1 666/4885CA2 2159/4885 |
| US-20050059693-A1 | Heterocyclic thioester and ketone hair growth compositions and uses | ACOT7, HSD17B7, ZDHHC7 | HTR2A 2684/4885CA1 2478/4885CA2 2928/4885 |
| US-20110117651-A1 | CELL ADHESION PROMOTING AGENT AND METHOD OF PROMOTING CELL ADHESION | EPCAM, HDGF, DSC1 | HTR2A 1169/4885CA1 1347/4885CA2 2238/4885 |
| US-20080176857-A1 | 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors | TBXA2R, P2RY4, PF4 | HTR2A 151/4885CA1 4737/4885CA2 2855/4885 |
| US-20150272947-A1 | INHIBITORS OF PROTEIN KINASES | CDK1, CDK2, CDK3 | HTR2A 3083/4885CA1 4127/4885CA2 3147/4885 |
| US-20030091931-A1 | Benzbisazole compound and optical recording medium containing the compound | DAO, CACNA1I, KCNB2 | HTR2A 671/4885CA1 757/4885CA2 215/4885 |
| US-20100160652-A1 | STEREOSPECIFIC METHOD FOR THE PREPARATION OF DIOXA-BICYCLOOCTANE NITRATE COMPOUNDS | TST, NOS3, NOS1 | HTR2A 2718/4885CA1 130/4885CA2 54/4885 |
| US-20110166137-A1 | Substituted Naphthalenyl-Pyrimidine Compounds | DPYD, TP53, TYMP | HTR2A 2599/4885CA1 4658/4885CA2 3587/4885 |
| US-20060088786-A1 | Rewritable optical information recording medium, recording and reproducing methods, as well as recording and reproducing apparatus | ALPG, TRPC6, GNRHR | HTR2A 277/4885CA1 74/4885CA2 660/4885 |
| US-20080214620-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | GLS, GLS2, GLUL | HTR2A 3732/4885CA1 2931/4885CA2 2281/4885 |
| US-20080194590-A1 | 4-Piperazinylthieno [2,3-D] Pyrimidine Compounds as Platelet Aggregation Inhibitors | PFKP, PF4, P2RY4 | HTR2A 712/4885CA1 4620/4885CA2 1740/4885 |
| US-20070244177-A1 | ENZYME INHIBITORS | ACHE, BACE1, MAOA | HTR2A 965/4885CA1 312/4885CA2 1473/4885 |
| US-20050171196-A1 | 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same | GLP1R, GCGR, GPR119 | HTR2A 601/4885CA1 877/4885CA2 221/4885 |
| US-20080293618-A1 | CYCLOPROPYL-FUSED PYRROLIDINE DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | DPP4, DPP3, DPP9 | HTR2A 4592/4885CA1 1046/4885CA2 1128/4885 |
| US-20210151797-A1 | ADDITIVE FOR NONAQUEOUS ELECTROLYTE SOLUTIONS, NONAQUEOUS ELECTROLYTE SOLUTION, AND LITHIUM ION SECONDARY BATTERY | TYK2, SLC9A1, SLC9B2 | HTR2A 2554/4885CA1 63/4885CA2 87/4885 |
| US-20130158071-A1 | PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF | CFTR, ABCB11, ABCC5 | HTR2A 4107/4885CA1 4716/4885CA2 1884/4885 |
| US-20100234397-A1 | ENZYME INHIBITORS | ACHE, MAOA, BACE1 | HTR2A 833/4885CA1 423/4885CA2 1673/4885 |
| US-20060100253-A1 | Novel compounds for the treatment of neurological disorders | PREP, BACE1, BCHE | HTR2A 1570/4885CA1 640/4885CA2 2140/4885 |
| US-20090269301-A1 | Novel Inhibitors of Glutaminyl Cyclase | GLS, GLS2, GLUL | HTR2A 2851/4885CA1 2969/4885CA2 891/4885 |
| US-20050148637-A1 | Heterocyclic ketone and thioester compounds and uses | BDNF, NTRK2, NTRK1 | HTR2A 3357/4885CA1 3342/4885CA2 4693/4885 |
| US-20080200475-A1 | 4-Piperazinothieno[2,3-D] Pyrimidine Compounds As Platelet Aggregation Inhibitors | PF4, TBXA2R, P2RY4 | HTR2A 259/4885CA1 4557/4885CA2 2288/4885 |
| US-20080221086-A1 | Novel Inhibitors of Glutaminyl Cyclase | GLS, GLS2, GLUL | HTR2A 2724/4885CA1 2745/4885CA2 693/4885 |
| US-20090018087-A1 | Novel Inhibitors of Glutaminyl Cyclase | GLS2, GLS, GLUL | HTR2A 309/4885CA1 1612/4885CA2 2665/4885 |
| US-20110224225-A1 | Inhibitors of protein kinases | CDK1, CDK2, CDK3 | HTR2A 3083/4885CA1 4127/4885CA2 3147/4885 |
| US-11644753-B2 | Resist composition and patterning process | HNRNPU, NSUN2, HNRNPR | HTR2A 3805/4885CA1 1910/4885CA2 472/4885 |
| US-20050215573-A1 | Novel inhibitors of glutaminyl cyclase | GLS2, GLS, GLUL | HTR2A 309/4885CA1 1612/4885CA2 2665/4885 |
| US-11733608-B2 | Resist composition and patterning process | HNRNPU, INSR, BICRA | HTR2A 3914/4885CA1 3056/4885CA2 2081/4885 |
| US-20210060168-A1 | ASIALOGLYCOPROTEIN RECEPTOR MEDIATED DELIVERY OF THERAPEUTICALLY ACTIVE CONJUGATES | ASGR1, FCGR2A, FCGR3B | HTR2A 2854/4885CA1 3305/4885CA2 3939/4885 |
| US-20200384111-A1 | MODIFIED CARBON NANOMATERIAL, NANOCLUSTER, SUBSTANCE DELIVERY CARRIER, AND PHARMACEUTICAL COMPOSITION | CHRM1, SLC67A1, NPSR1 | HTR2A 823/4885CA1 51/4885CA2 61/4885 |
| US-20080207715-A1 | Novel Inhibitors of Glutaminyl Cyclase | GLS, GLS2, GLUL | HTR2A 2522/4885CA1 2940/4885CA2 940/4885 |
| US-20240239745-A1 | METHOD FOR SYNTHESIZING BILIRUBIN | CYP7A1, UGT1A3, UGT1A1 | HTR2A 4323/4885CA1 4574/4885CA2 4654/4885 |
| US-20070117801-A1 | Indane derivatives as modulator of ion channels | KCNJ2, TRPV1, KCNJ1 | HTR2A 379/4885CA1 1026/4885CA2 182/4885 |
| US-20040209860-A1 | compounds having a (biphenyl-2-yl)oxycarbonylamino- or (biphenyl-2-yl)aminocarbonylamino-substituted (2-7C)azacycloalkyl or (5-10C)azabicycloalkyl group; and a 2-(4-hydroxyphenyl)-2-hydroxyethylamino group; treating asthma or chronic obstructive pulmonary disease; providing bronchodilation | ADRA2C, ADRB2, AHR | HTR2A 52/4885CA1 4518/4885CA2 1366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.